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Abstract
Fibroblast activation protein (FAP), a membrane prolyl-specific proteinase with both dipeptidase and endo-
peptidase activities, is overexpressed by reactive stromal fibroblasts during epithelial-derived cancer growth.
FAP digests extracellular matrix as tissue is remodeled during cancer expansion and may also promote an immuno-
tolerant tumor microenvironment. Recent studies suggest that nonspecific FAP inhibitors suppress human cancer
xenografts in mouse models. Prolyl oligopeptidase (POP), another prolyl-specific serine proteinase, is also elevated
in many cancers and may have a regulatory role in angiogenesis promotion. FAP and POP cell–associated activities
may be targets for diagnosis and treatment of various cancers, but their accessibilities to highly effective specific
inhibitors have not been shown for cells important to cancer growth. Despite their frequent simultaneous expres-
sion in many cancers and their overlapping activities toward commonly used substrates, precise, separate measure-
ment of FAP or POP activity has largely been ignored. To distinguish each of the two activities, we synthesized
highly specific substrates and inhibitors for FAP or POP based on amino acid sequences surrounding the scissile
bonds of their respective putative substrates. We found varying amounts of FAP and POP protein and activities on
activated fibroblasts, mesenchymal cells, normal breast cells, and one breast cancer cell line, with some cells
exhibiting more POP than FAP activity. Replicating endothelial cells (ECs) expressed POP but not FAP until tubulo-
genesis began. Targeting FAP-positive cells, especially mesenchymal stem cells and cancer-associated fibroblasts
for inactivation or destruction, and inhibiting POP-producing EC may abrogate stromal invasion and angiogenesis
simultaneously and thereby diminish cancer growth.
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Introduction
As a primary malignancy invades surrounding tissues or metastasizes
to distal sites, even tumor cell growths of 1- to 2-mm diameter require
a stromal microenvironment composed of activated fibroblasts, endo-
thelial cells (ECs) involved in tubulogenesis, and extracellular matrix
(ECM) that is constantly remodeled to accommodate growth. In
addition, precursor mesenchymal stem cells (MSCs), their putative
derivative cancer-associated fibroblasts, and cancer stem cells may also
be present. The prolyl-specific serine proteinase, fibroblast activation
protein (FAP), a type II integral membrane protein, is regularly over-
expressed on the stroma of >90% of epithelial-derived cancers and
their metastases [1–3]. FAP is produced transiently by activated stromal
fibroblasts during embryogenesis [4], the latter stages of wound healing
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[3], in certain pathologic states in which fibrous tissue growth is a con-
spicuous feature [5–9], and occasionally on normal fibroblast or pan-
creatic α-cells. FAP is not characteristically found on normal tissues or
benign tumors [2,3,10]. Taken together, these observations prompted
the suggestion that FAP may carry powerful potential as an ideal ther-
apeutic target in a number of cancers [11–14].
The in vivo function of membrane-inserted FAP remains poorly
understood, likely because a biologic substrate for its proteinase activ-
ity has not been definitively established; however, reports that FAP
cleaves gelatin [2,15,16] and partially denatured or degraded type I
collagen [17,18] suggest that FAP helps digest ECM components as
tissue is remodeled to accommodate cancer expansion [2,19,20].
Paradoxically, activated fibroblasts not only digest ECM but also syn-
thesize ECM components of the stromal scaffolding that support cell
division and motility during neoplastic growth [21]. FAP proteolytic
activity has been considered the most obvious useful property to tar-
get for inhibition when designing new therapeutic approaches to the
large number of FAP-containing cancers [11,12]. Santos et al. [22] have
shown that genetic deletion or pharmacologic inhibition of FAP by
glutamyl-proline boronic acid (Glu-boroPro) decreased stromal growth
in mouse models of lung and colon cancer. Unfortunately, however,
Glu-boroPro has an exceptionally short plasma half-life before cyclizing
and losing inhibitory activity [23]. Moreover, it also inhibits dipeptidyl
peptidase IV, which is important in plasma glucose regulation and
immune function [24]. Hence, despite inhibiting FAP and suppressing
tumor growth, Glu-boroPro is not likely to be therapeutically useful in
cancer [25].
The accessibility and measurement of cell membrane FAP activity
and its inhibition remains incompletely studied, particularly with respect
to the different cells commonly found in tumor microenvironments.
Additionally, although not always appreciated, the measurement of
FAP activity is confounded by another prolyl endopeptidase, namely,
prolyl oligopeptidase (POP), which is expressed by a number of normal
cell types and is commonly elevated in many cancers [26]. Recently,
POP has been suggested to make secondary cleavages in partially
degraded thymosin-β4 to yield the derivative peptide, acetyl-SDKP,
which appears to be a potent stimulator of angiogenesis [27]. Both
FAP and POP activities are regularly measured using nonspecific sub-
strates such as Z-Gly-Pro-AMC or succinyl-Gly-Pro-AMC, neither of
which distinguishes between the two activities [28]. Consequently, total
prolyl-specific endopeptidase activity, which is often attributed to FAP
alone, may also include POP activity and thereby complicate interpreta-
tions about the effects of inhibiting either enzyme on cancer growth,
particularly since both enzymes appear commonly overexpressed by
several cell types that comprise metastatic tumor microenvironments.
Our discovery of antiplasmin-cleaving enzyme (APCE) in human
plasma and its virtual identity with FAP has made APCE a useful
FAP surrogate for constructing highly specific and sensitive low molec-
ular weight pseudo-peptide substrates and inhibitors for APCE or FAP
[15,28–30]. Previously published preferred substrate peptide sequences
for cleavage by POP [31] proved valuable for the design and synthesis
of a specific and sensitive inhibitor of POP. We now report measure-
ments of membrane-associated FAP and POP activities over time and
show that each can be effectively inhibited while on live cells that typify
microenvironments of expanding and metastasizing tumor niches,
namely, MSCs, activated fibroblasts, two breast cancer cell lines, and
ECs. Our results suggest that the two proteinases may be synergistic
for tumor growth. Either enzyme is a potential target for rapid, specific
inhibition by pseudo-peptide inhibitors that were designed to be coher-
ent with active site structural features and thereby present unique ther-
apeutic potential for treatment of epithelial-derived malignancies.
Materials and Methods
Cell Culture
Fibroblasts, WI-38 and WI-38 VA13 2RA (VA-13), breast cancer
cells, MDA-MB436 (MDA) and HCC1419 (HCCs), and normal
breast cells, MCF-12A, were all purchased from American Type Culture
Collection (ATCC, Manassas, VA). Human dermal microvascular
endothelial cells (HMVECd) and MSCs were purchased from Lonza
(Walkersville, MD). All cells were authenticated by the companies and
used within 6 months of purchase or recovery from cryopreservation.
WI-38 and VA-13 were grown in minimum essential medium (Media-
tech Inc, Manassas, VA) supplemented with 10% fetal calf serum (Gibco,
Grand Island, NY), 2 mM GlutaMAX-1 (Gibco), and 1 mM sodium
pyruvate (Gibco). MDA and HCCs were grown in Dulbecco’s modified
Eagle’s medium (DMEM; Mediatech Inc) supplemented with 10% fetal
calf serum. MCF-12A and HMVECd were grown in EGM2-MV
(Lonza) with all provided supplements, unless otherwise specified.
MSCs were grown in MSCGM (Lonza).
Monoclonal Antibody Production
Human APCE was purified as previously described [29] and used
as the antigen for monoclonal antibody (mAb) production. The
hybridoma cells were produced at the Hybridoma Center for Agri-
cultural and Biological Sciences at Oklahoma State University. After
initial screening against pure APCE by direct ELISA, the positive
cells were cloned three times by limiting dilution. Selected antibodies
were produced in serum-free media (Gibco) in roller bottles, then
purified using MEP HyperCel (Pall, Port Washington, NY) chroma-
tography and isotyped using the Pierce Rapid Isotyping Kit (Thermo
Scientific, Waltham, MA). Of 24 mAbs identified, mAb 6D2, an
IgG1κ antibody, recognized both APCE and FAP by ELISA or West-
ern blot analysis with the greatest sensitivity and was used in these
studies. Mouse F19 mAb to FAP was produced and purified from
cultures of hybridoma cells purchased fromATCC and used for confocal
imaging and immunoprecipitation (IP).
Immunostaining
Selected normal or neoplastic cells were grown to confluency in
10-cm tissue culture dishes, rinsed in phosphate-buffered saline
(PBS), and lysed on the plate in 1 ml of 2× Laemmli denaturing
sample buffer with DTT for whole-cell lysates. Membrane and cyto-
solic fractions were prepared from confluent tissue culture dishes
using the Mem-PER Kit (Pierce) as per the manufacturer’s instruc-
tions. Samples were electrophoresed under reducing conditions on
4% to 12% Bis-tris sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS-PAGE) gels (Invitrogen, Grand Island, NY) and
transferred to nitrocellulose for Western blot analysis. After blocking
with 3% BSA/TBS-Tween (TBST), blots were incubated with a
combination of 0.5 μg/ml mAb 6D2 (anti-FAP), 0.1 μg/ml anti–α-
tubulin (Sigma, St Louis, MO; #6199), and 0.1 μg/ml anti-actin (Abcam,
Cambridge, MA; 2Q1055), in 1% BSA/TBST, and then washed and in-
cubated with 1:60,000 goat anti–mouseHRP (Thermo Fisher, Pittsburgh,
PA). Blots for POP were blocked with 3% BSA/TBST, then incubated
with a combination of 0.1 μg/ml goat anti-POP (R&D Systems,
Minneapolis, MN; #AF4308), 0.1 μg/ml anti–α-tubulin (Sigma;
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#6199), and 0.1 μg/ml anti-actin (Abcam; 2Q1055) in 1.5% BSA/0.5
MNaCl/TBST. After washing in the same buffer, blots were incubated
with 1:18,000 rabbit anti–goat HRP (R&D Systems; #HAF017) in
1.5% BSA/0.5 M NaCl/TBST. ECL-Plus (Thermo Fisher) was added
and blots were visualized on RPI blue radiographic film.
Confocal analysis of FAP protein in cells was accomplished first by
growing cells to confluence on four-well glass chamber slides (Lab-Tek,
Waltham, MN). The cells were fixed with 0.75% paraformaldehyde,
blocked with 1% BSA/PBS, and then incubated with mouse F19 mAb
(2 μg/ml) or isotype control antibody, MOPC 21 (Sigma; 2 μg/ml) in
0.1% BSA/PBS, with 0.1% saponin. After washing, the slides were incu-
bated with goat anti–mouse Alexa Fluor 568 (Invitrogen) at 1:2000 in
0.1% BSA/PBS and then mounted with Prolong Gold/4′,6-diamidino-
2-phenylindole (DAPI;Molecular Probes, Grand Island, NY). Cells were
visualized using a Leica TCSNTMicroscope fittedwith a 40× Plan Fluotar
1.0 NA oil immersion objective. Images were analyzed using Leica TCS
and Volocity software.
Protein Characterization
Cells of each type were grown to confluence in 10-cm tissue culture
dishes, rinsed in PBS, and then lysed in 1 ml of ice-cold IP buffer
containing 1% Triton/150 mM NaCl/10 mM Tris (pH 7.5)/1 mM
EDTA/1 mM EGTA/0.5% NP-40/10% sucrose with cOmplete
ULTRA protease inhibitor cocktail (Roche, Indianapolis, IN) added.
Whole-cell lysates were centrifuged to remove detergent-insoluble pro-
teins. mAb F19 (5 μg/ml) was added and allowed to bind overnight at
4°C. Then, 25 μl of 75% slurry of Protein G beads (Amersham, Pittsburgh,
PA) in TBS was added and incubated for 1 hour at 4°C. Protein G beads
were spun down, washed three times with IP buffer, resuspended in load-
ing buffer, and boiled for 5 minutes; the beads were removed by centri-
fugation and a portion of the supernatant was electrophoresed under
reducing conditions on 4% to 12% Bis-tris SDS-PAGE gels. To confirm
the presence of FAP, the regions of each lane corresponding to the mo-
lecular weight of FAP were excised and the proteins within each gel slice
were reduced with tris[2-carboxyethyl]phosphine, then alkylated with
iodoacetamide, and digested with trypsin as described by the In-gel Tryp-
tic Digestion Kit protocol (Thermo Fisher). Each trypsin digest sample
was analyzed by high-performance liquid chromatography–tandem mass
spectrometry (LC/MS/MS) on a nanoscale Dionex UltiMate 3000
HPLC equipped with an Acclaim PepMap C18 column (75-μm internal
diameter × 15-cm length with 3-μm particles) connected to an AB-Sciex
QSTAR Elite mass spectrometer. The peptide molecular weights and
MS/MS fragment ion spectra observed for each peptide were used to
query an National Center for Biotechnology Information comprehensive
nonidentical human protein database (updated 31 January 2011) loaded
on an in-house MASCOT database server (version 2.3).
Inhibitors and Substrate
The pseudo-peptide inhibitor, acetyl-Arg-AEEA-(D)Ala-(L)boroPro
[AEEA, 2-(2-(2-aminoethoxy)ethoxy)acetic acid], M83, with dual
FAP (K i = 5.7 nM) and POP (Ki = 7.4 nM) inhibition; the specific
POP inhibitor, acetyl-Lys-Leu-Arg-(L)boroPro, J94 (K i < 100 nM);
and the substrate for both FAP and POP, acetyl-Arg-AEEA-Gly-Pro-
AMC, C95, were designed, synthesized, and characterized by us as
previously reported [28]; all are soluble in aqueous buffers. The inhibi-
tors (J94 and M83) were dissolved in Hank’s balanced salt solution
(HBSS; Gibco) at 1 mM and stored at −20°C. The substrate (C95)
was dissolved in HBSS at 2.5 mM and stored at 4°C. FAP and POP
at equimolar concentrations cleaved C95 substrate at equivalent rates
(data not shown).
Whole-cell Activity Assays
Cells were cultured in normal growth media unless otherwise stated.
For cells grown in media with selected components either withheld or
added, and depending on each experimental design as indicated in the
Results section, growth times were chosen from 7 to 14 days in specific
media before plating for activity assays. For activity assays, cells were
plated onto 96-well black-sided, clear bottom tissue culture plates
(Costar) at densities selected for achieving confluency in 3 days. Cell
densities varied with cell type and the selected growth media; the num-
ber of cells necessary for plating was estimated from pilot experiments.
After 3 days of growth, cultures were washed with HBSS. The wash
solution was replaced with 188 μl of fresh buffer (HBSS) and 2 μl of
either buffer (Control) or M83 or J94 inhibitor (10 μM final) was
added. Ten microliters of fluorescent substrate, C95, was added to give
a final concentration of 125 μM, and fluorescence was measured with
time at 360/460 nm excitation/emission wavelengths using an FL600
microplate fluorescence reader (Bio-Tek Instruments, Winooski, VT).
Fluorescence units were converted to FAP units/100,000 cells by using
a conversion factor determined from an APCE standard curve of prolyl-
specific endopeptidase activity, such that 1 FAP unit is equivalent to the
fluorescence produced by 1 ng of APCE/min. Since FAP and POP
cleave the C95 substrate at an equivalent rate, both FAP and POP
activities are expressed as FAP units in all figures.
For tube formation assays, Matrigel (BD Biosciences, San Jose, CA;
80 μl) was added to black-sided, clear bottom 96-well plates as above
and allowed to gel at 37°C for 30 minutes. Then, 15,000 HMVECd
in EC medium without serum were added and allowed to settle for
1 hour. Either buffer, the M83 inhibitor, or the J94 inhibitor (10 μM
final) was added, and the assay then started by adding the dual FAP/
POP fluorescent C95 substrate. The reader was maintained at 37°C
and fluorescence was measured with time for 18 hours.
Results
FAP/APCE and POP are prolyl-specific serine endopeptidases, with
the proteolytic activity of POP restricted to peptides less than about
30 residues [32]. FAP is membrane-inserted and POP is membrane-
associated [33,34], while APCE circulates in blood, possibly as a
shed-soluble derivative or splice variant of FAP [15]. Nonspecific
dipeptides containing prolyl boronic acid compounds or mutations
of the serine active site in FAP inhibit FAP proteolytic activity on
cancer-associated fibroblasts and diminishes cancer growth [20,22].
To date, the accessibility and rapidity by which inhibitors block
activity of membrane-bound FAP have not been directly assessed.
POP, commonly expressed by neoplasms [6,26,34–36], manifests
overlapping proteolytic activity with FAP/APCE when measured as
usual with nonspecific fluorescent peptide substrates such as Z-Gly-
Pro-AMC or succinyl-Gly-Pro-AMC [28]. Efforts to use inhibitors
to separate the two enzymatic activities have likewise been compro-
mised by significant inhibition of both FAP and POP [28]. The prob-
lem of measuring FAP and POP activities separately in biologic or
pathologic scenarios where either may play a critical role has received
scant attention, which we now address through the use of specific FAP
and POP substrates and inhibitors designed and characterized in our
laboratory [28].
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In Figure 1A, confocal microscopy of immunostained saponin-
permeabilized WI-38 fibroblasts shows abundant FAP, most of which
appears membrane-associated. As reported, FAP was absent in SV-40
transformed VA-13 fibroblasts [10]. Figure 1B shows results for FAP
and POP activity assays, using highly selective, specific substrates and
inhibitors we previously described [28]. Overlying medium was first
removed from each cell culture after which cells were washed with
physiologic buffer and overlaid with fresh buffer. FAP or POP inhib-
itor was added, and each culture assayed with time for both FAP and
POP activities. By using the specific substrate, C95, that is cleaved
only by FAP or POP in conjunction with the high affinity POP inhib-
itor, J94, that has strict specificity for POP, but none toward FAP, we
were able to measure each enzyme’s activity [28]. For each cell type,
total prolyl-specific endopeptidase activity on intact cell membranes
was determined using C95 substrate, which is cleaved at equal rates
by FAP or POP; on parallel cultures, J94 inhibitor was added to block
solely that activity due to POP, thereby defining the remaining endo-
peptidase activity as uniquely attributable to membrane-associated FAP
(Figures 1B, 3, 4B, 5B, 6, and 8B). As expected, the dipeptidase,
DPPIV, neither cleaved C95 substrate nor was it inhibited by M83
or J94. Our previous studies showed that APCE and FAP have essen-
tially identical activities [15], thereby allowing the use of an APCE stan-
dard curve to determine moles of active FAP on the cell surface and,
hence, the number of FAP proteinase molecules per cell. Therefore,
knowing the FAP activity and number of WI-38 fibroblasts in
a confluent well, each cell was estimated to have ∼117,000 FAP
molecules on its membrane surface. Figure 1C demonstrates FAP by
Western blot and Figure 1D indicates that the majority of FAP is
membrane-associated, with a lesser amount in the cytosol, which agrees
with our confocal results. Figure 1E shows POP by Western blot
in both WI-38 and VA-13 fibroblasts, although the activity assay
did not detect any surface accessible POP activity in VA-13 cells.
The majority of POP is cytosolic with a significant fraction being
membrane-associated, which agrees with our assay results of cell surface
POP activity (Figure 1F ).
Neither FAP nor POP activity was found in media that had been
in contact with cells for 3 days, indicating that neither enzyme was
shed or released (data not shown). When fresh buffer was again
placed over the cells, both FAP and POP activities were found to
be unchanged and immediately detectable, thereby supporting the
membrane location of both enzymes. As can be seen in Figure 1B,
WI-38 fibroblasts yielded higher FAP than POP activity. In Figure 1C ,
immunoblot analyses of lysates derived from a specified number of
cells of each cell type, using the cellular content of α-tubulin (50 kDa)
and actin (43 kDa) as protein load controls, showed relative FAP
levels in accord with those estimated by confocal microscopy of cor-
responding immunostained cells or by endopeptidase activity measure-
ments. As shown in Figure 2, amino acid sequence determinations for
tryptic peptides of the isolated putative FAP protein band from each
cell type ensured that the ∼100 kDa band from WI-38 fibroblasts
was indeed FAP.
Figure 3 illustrates the effectiveness and rapidity of FAP and POP
inhibition by the pseudo-peptide inhibitor construct, M83. Cultured
W-I38 cells were exposed to the inhibitor at either the beginning of
Figure 1. Characterization of FAP and POP in fibroblasts. (A) Confocal images of permeabilized WI-38 and VA-13 fibroblasts grown on
plastic slides and labeled with mouse anti-FAP mAb F19 followed by anti–mouse Alexa Fluor 568 (red) and the DNA stain DAPI (green).
(B) FAP and POP activities of fibroblasts grown on plastic wells as measured by cleavage of fluorescent substrate C95 and using a POP
specific inhibitor J94 to separate the two activities. One FAP unit = Δfluorescence/min on cleavage of C95 by 1 ng of APCE. (C) Immuno-
stains of cell lysates from fibroblast cultures using mouse anti-FAP mAb 6D2. One nanogram of APCE served as a positive control, while
intracellular contents of α-tubulin (50 kDa) and actin (43 kDa) were used for standardizing the amount of cell lysate protein applied in each
lane. (D) Immunostains of cell lysates and membrane and cytosol fractions fromWI-38 fibroblast cultures using mouse anti-FAP mAb 6D2.
One nanogram of APCE served as a positive control. (E) Immunostains of cell lysates from fibroblast cultures using goat anti-POP. One
nanogram of POP served as a positive control, while α-tubulin (50 kDa) and actin (43 kDa) were used for standardizing loads. (F) Immuno-
stains of cell lysates and membrane and cytosol fractions fromWI-38 fibroblast cultures using goat anti-POP. One nanogram of POP served
as a positive control.
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the assay or after 2 hours of incubation with the C95 substrate that is
cleaved by FAP or POP. After an increasing fluorescent signal indi-
cated the accrual of significant proteolytic activity, the addition of
even nanomolar concentrations of the M83 inhibitor instantly abol-
ished endopeptidase activity as evidenced by lack of further fluores-
cence increase.
As shown in Figure 4, three methods of assessment, namely, con-
focal microscopy, Western blot analysis, and high specificity endo-
peptidase activity, indicated that human MCF-12A or human MDA
contained far less FAP protein and FAP activity than observed for
WI-38 activated fibroblasts (Figure 1). While POP activity for MCF-
12A cells and WI-38 fibroblasts was similar, human MDA had about
five times that amount. Whole-cell lysates of MCF-12A, MDA, and
HCCs were subjected to Western blot analysis, which demonstrated
an approximately equal amount of POP in all cells (Figure 4D).
MDA had greater POP activity than the other two cell types, but the
assay only measures activity of cell surface POP and not intracellular
enzyme. HCCs contained neither FAP protein nor FAP activity. To
date, overexpression of POP in neoplasms remains unexplained, but
recent results of Myohanen et al. [37] suggest that POP may be respon-
sible for a second-step proteolytic cleavage in the autoregulation of
thymosin-β4 that yields the derivative tetrapeptide, acetyl-SDKP, a
potent stimulator of angiogenesis.
In Figure 5A, confocal microscopy of cultured normal HMVECd
on plastic demonstrated that cell-associated FAP was only occasion-
ally encountered (the figure shows a field containing a rare positive
cell). Western blot analysis of HMVECd lysates lacked a band con-
sistent with FAP protein (Figure 5C ). Likewise, HMVECd were
devoid of FAP activity (Figure 5B), but HMVECd cultures did con-
tain considerable POP activity and the presence of the protein was
confirmed by Western blot (Figure 5D). However, as shown in
Figure 6B, when grown on Matrigel and allowed to form tubules
over an 18-hour period, significant amounts of both FAP and
POP activities were expressed and easily detectable. POP expression
began just before capillary-like tubules started forming and continued
Figure 2. Amino acid sequence coverage for FAP isolated from four human cell types. Protein was purified by immunoprecipitation and
SDS-PAGE followed by sequence determination by LC/MS/MS; human MSCs ( ), 51% (coverage FAP sequence); WI-38 fibroblasts
( ), 42%; MDA ( ), 41%; and HMVECd deprived of hydrocortisone ( ), 6.4%. In each case, the FAP-containing
region of the gel was located by reference to a 100-kDa protein standard band in an adjacent lane.
Figure 3. Dose-response inhibition of FAP activity on WI-38 fibro-
blast surfaces by M83. WI-38 fibroblasts were grown on plastic
and washed once with HBSS, after which the M83 inhibitor (10 μM)
in HBSS was added at zero time to one set and buffer only to the
other four sets. The fluorescent substrate C95 was added to all sets
of wells andΔfluorescence/min, reflecting cleavage of C95 over time,
was allowed to proceed for 2 hourswhen 10 μM, 1 μM, or 100 nMof
theM83 inhibitorwas added toeachof three sets ofwells. As shown,
each inhibitor concentration instantly, and essentially totally, inhib-
ited the proteolytic activity of FAP on the cell surface.
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as the complexity of the tubule network increased. Interestingly,
detectable FAP expression as reflected by proteolytic activity began
∼3 to 4 hours after tubulogenesis (i.e., 8 hours from plating HMVECd)
and continued to increase during the subsequent 18-hour period of
growth. These findings suggest that POPmay be critical to the initiation
and propagation of vessel formation, with the timing of FAP expression
synchronized with ECM invasion by the forming capillary-type tubules
[19,22,38]. While FAP mRNA is upregulated coincident with cap-
illary formation [39], the observation that proteolytically active FAP
protein becomes easily detectable and increases progressively with
tubulogenesis has not been reported previously. The temporal rela-
tionship of FAP production by ECs and the possibility that tissue-
specific vascular FAP expression occurs could account for not always
observing FAP in ECs [7,40].
As shown in Figure 7, when HMVECd and other selected cell
types were stressed by removing hydrocortisone (hyc) from growth
media, FAP became substantially overexpressed as detected by Western
blots of cell lysates and corresponding increases in FAP proteolytic
activity. Identification of the overexpressed protein as FAP was vali-
dated by amino acid sequence determination as shown in Figure 2.
In Figure 7A, the greatest overexpression of FAP in response to omis-
sion of hyc in growth media was seen with MCF-12A. When hyc was
restored to concentrations used for growth of normal cells in culture,
overexpression of FAP by MCF-12A cells was totally reversed
[Figure 7B, compare MCF-12A(−)hyc and MCF-12A(−)hyc/(+)hyc].
In contrast, removal of various growth factors (vascular endothelial
growth factor, basic fibroblast growth factor, epidermal growth factor,
and insulin-like growth factor) from growth media had no apparent
effect, even after 42 days of culture.
Cancerous MSCs may be the best target in the search for a broadly
applicable common denominator or “pan-tumor” approach for treat-
ing a large number of cancers [41,42]. We are aware of only one report
showing FAP to be associated with MSC membranes as evidenced by
immunoselection of MSCs from human cryopreserved bone marrow
with a FAP mAb [43]. This prompted us to question whether MSCs,
as the putative precursor to activated stromal fibroblasts [44], also
expressed proteolytically active, membrane-bound FAP, and if so,
how much relative to the activated fibroblast, and could it be readily
inhibited? Confocal microscopy of permeabilized human mesenchymal
cells in Figure 8A shows significant amounts of cytosolic andmembrane-
associated FAP, more or less similar to WI-38 fibroblasts. Western
immunoblots of mesenchymal cell lysates (Figure 8C ) confirmed a
large amount of FAP present and did identify POP protein as well
(Figure 8E ). LC/MS/MS analysis of tryptic peptides from digestion
of the ∼100 kDa band in lysates of MSCs established the protein band
as a subunit of homodimeric FAP (Figure 2). When mesenchymal
membrane and cytosolic fractions were separated and subjected to
Western blot analysis, it was clear that FAP is abundant on membranes
and is in the cytosol to a lesser extent (Figure 8D). In contrast, the
majority of POP is in the cytosol, with a lesser amount in the mem-
brane fraction (Figure 8F ). Mesenchymal cells and fibroblasts had
about the same amount of FAP and POP activity, which might be
expected given that mesenchymal cells are believed precursors of fibro-
blasts [44]. AssumingMSC and fibroblast membranes are impermeable
Figure 4. Characterization of FAP and POP in normal breast and breast cancer cells. (A) Confocal images of permeabilized MCF-12A,
MDA, or HCCs grown on glass slides and labeled with mAb F19 to FAP followed by anti–mouse Alexa Fluor 568 (red) and DAPI (green).
(B) FAP and POP activities on surfaces of normal and breast cancer cells grown on plastic wells as measured by cleavage of fluorescent
substrate C95 and using the POP specific inhibitor J94 to separate the two activities. One FAP unit = Δfluorescence/min on cleavage of
C95 by 1 nanogram of APCE. (C) Immunostains of cell lysates from normal and breast cancer cell cultures, using mAb 6D2 to FAP. APCE
(1 ng) was used as a positive control, while intracellular contents of α-tubulin (50 kDa) and actin (43 kDa) were used for standardizing the
amount of cell lysate protein applied in each lane. (D) Immunostains of cell lysates from normal and breast cancer cell cultures using
goat anti-POP. POP (1 ng) was used as a positive control, while α-tubulin (50 kDa) and actin (43 kDa) served as load controls.
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to C95 substrate because of the latter’s positive charge and lack of
hydrophobicity, cytosolic FAP activity in live cells would not likely con-
tribute to measurement of membrane activity.
Discussion
FAP continues to be a potential diagnostic or therapeutic target
because it is 1) overexpressed by activated stromal fibroblasts in
epithelial-derived human malignancies [11,12,22] and 2) absent in
normal adult tissues and benign tumors [11,12,22]. Santos et al.
[22] showed that targeted gene disruption or pharmacologic inhibi-
tion of FAP proteinase activity slowed or halted tumor growth in
mouse models of endogenous lung cancer and human colon cancer.
In both tumor scenarios, cancer cell proliferation decreased, collagen
increased, andmyofibroblast content and blood vessel density decreased.
In those studies, however, the two inhibitors of FAP, e.g., Glu-boroPro
or Val-boroPro, are also known to inhibit physiologically important
DPPIV; both also inhibit POP; and both undergo cyclization, causing
abbreviated in vivo survival that limits therapeutic potential.
Recently, Kraman et al. [45] reported that absence of FAP-expressing
cells in mice allowed effective vaccination strategies for immunologic
control of epithelial cell–derived cancer growth. In that study, no direct
efforts were reported for determining whether FAP proteolytic activity
was necessary for immunosuppressive effects within the tumor environ-
ment. In accord with both proteolytic and nonproteolytic roles for FAP
in malignant growth, Huang et al. [46] recently suggested that FAP
proteolytic function is important in ECM degradation but that other
undefined properties (possibly immunologic) of FAP may promote
tumor growth.While the function of FAP within malignancies remains
poorly understood, most efforts to assess FAP as a therapeutic target
have involved inhibiting its proteinase activity or using the latter to
cleave oncologic drugs attached to peptides targeted to FAP [47].
Characterizing the proteolytic activity of membrane-inserted FAP has
been unusually difficult, since a physiologic or pathologic substrate has
not been definitively identified. We used the amino acid sequence
surrounding the scissile bond of precursor α2AP, a FAP substrate, to
design stable and highly effective water-soluble inhibitors of APCE
and FAP [28]. In the process, we discovered that a positively charged
residue in P6 or P7 augmented substrate cleavage rate significantly
[30,48], and this proved useful in developing our most effective FAP
inhibitor, M83, and its analogue fluorescent substrate, C95 [28,30].
Both manifested high affinity and good specificity for FAP and, to a
significant extent, for another prolyl-specific serine proteinase family
member, namely, POP, which we, like others [34,49], found associated
with selected normal and cancer cell lines.
We used the C95 FAP and POP substrate as well as the M83
inhibitor of both FAP and POP in conjunction with the highly specific
J94 POP inhibitor, which had no effect on FAP, to quantitate and
assign endopeptidase activity on cell membrane surfaces to its respective
Figure 5. Characterization of FAP and POP in microvascular ECs.
(A) Confocal images of permeabilized HMVECd grown on glass
slides and labeled with mAb F19 to FAP followed by anti–mouse
Alexa Fluor 568 (red) and DAPI (green). (B) FAP and POP activities
of ECs grown on plastic wells measured by exactly the same
methods described in Figures 1 and 4. (C) Immunostaining for
FAP performed as described in Figures 1 and 4. (D) Immunostain-
ing for POP performed as described in Figures 1 and 4.
Figure 6. FAP and POP activities in microvascular ECs. (A) HMVECd
were plated on plastic wells and allowed to settle for 1 hour, then
inhibitors and substrates were added and fluorescence was mea-
sured over time for 18 hours. (B) HMVECd were plated on Matrigel,
allowed to settle for 1 hour to initiate tubule formation, and assayed
for FAP and POP activities as in A. Note that POP activity is detect-
able from the start in both assay conditions, but FAP activity only
appears in the Matrigel assay at ∼4 hours after tubule formation.
Each point represents 15 readings over three separate experiments.
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enzyme of origin. While POP cleaves selected peptides of less than
about 30 residues, its biologic function remains unknown, as POP still
lacks proven biologic substrate(s) that yield definitive physiologic effects
[50]. Interestingly, however, POP recently has been proposed to have a
significant role in angiogenesis by secondarily cleaving a derivative
peptide from the ubiquitously tissue-distributed thymosin-β4 to yield
the tetrapeptide, acetyl-SDKP, a potent stimulator of angiogenesis [36].
Our results show that activated fibroblasts, i.e., those that are 1) rap-
idly dividing, 2) highly mobile, 3) contain α-smooth muscle actin
(myofibroblasts), and 4) manifest enhanced ECM deposition, also have
impressive amounts of FAP on their membranes with lesser amounts in
the cytosol (Figure 1, A and D). Cancer-associated fibroblasts are acti-
vated fibroblasts that typically help form the stromal scaffolding of
metastatic epithelial-derived tumor microenvironments. Assays of
FAP or POP activity in the nonserum-containing media in which cells
grew, or in buffer washes of those cell cultures, were always devoid of
proteolytic activity, thereby supporting both enzymes as membrane-
associated and in conformations that allow proteolytic activity to be
easily and rapidly inhibited. Subtraction of the activity specifically
inhibited by the J94 POP inhibitor provided an estimate of accessible
FAP proteolytic activity. Assuming equivalent recoveries of FAP from
different cell types, the amount of FAP protein and FAP proteinase
activity in WI-38 fibroblasts exceeded that in any other cell, except
for MSCs. Immunoreactive FAP protein was recovered from WI-38
fibroblasts and MDA, HMVECd deprived of hyc, or MSCs, and in
each case gave essentially an identical amino acid sequence to that
established for FAP [15]. Proteolytic assays confirmed that viral-
transformedVA-13human fibroblasts lacked bothmembrane-associated
FAP and POP activities.
We demonstrated small amounts of FAP and POP activity and
protein in normal breast cells, about the same amount of FAP activity
in human metastatic breast cells; however, the latter cells contained
about six times the amount of POP activity compared to normal breast
cells. It seems reasonable that within hormonally induced cyclical tissue
responses, an occasional normal breast parenchymal cell might be
induced to express a small amount of FAP and POP. HCC1419 intra-
luminal primary breast cancer cells contained barely detectable FAP by
immunostaining, and no assayable FAP proteinase activity; POP activity
was greatly reduced, but POP protein, likely intracellular, was easily de-
monstrable. Within a growing HCC1419 tumor, however, this does
not preclude the possibility that requisite stroma within the breast can-
cer malignancy may express FAP and POP. The basis of abundant POP
activity found on MDA (Figure 4) remains obscure, despite such in-
creases having been noted before in several other malignancies
[26,34]. Larrinaga et al. [34] reported POP on cell membranes of var-
ious human cancers but usually in amounts not much different than
those on corresponding normal cell types; however, cytosolic POP
within cancer cells was regularly significantly increased beyond that
in corresponding normal cells, which is in keeping with our finding
for HCCs.
ECs (HMVECd) grown on plastic contained a rare FAP-positive
cell by immunostaining but no detectable FAP protein by immuno-
blot analysis or proteinase assay; however, significant POP activity
was expressed as confluence was achieved, perhaps related to its pro-
posed role in capillary tube formation [36], but as expected, tube
formation did not occur on plastic, and POP expression continued
unabated. FAP was not expressed during the 72-hour growth period
(Figure 5B). In contrast, when grown on Matrigel, by about 4 hours
the HMVECd cells began to align progressively in tubular structures
as POP expression continued to increase (Figure 6B). Interestingly,
FAP activity became demonstrable shortly after tube-like capillaries
began forming (Figure 6B), and by ∼18 hours, well-defined capillary-
like networks dominated. These results prompted the speculation that
expression of proteolytically active FAP might be synchronized with
capillary growth to foster invasiveness of developing microvasculature
into the ECM [38]. Aimes et al. [39] noted endothelial expression of
mRNA transcripts of several serine proteinases (including FAP) in
association with the nature of the culture substratum and progression
of angiogenesis. Our finding of increasing FAP proteolytic activity
expands their report by demonstrating that increased FAP mRNA
is actually translated during tubule formation. Interestingly, Cavallo-
Medved et al. [51] noted that concentrations of other selected proteinases
Figure 7. FAP activity and FAP protein levels in stressed cells. WI-38
fibroblasts, MCF-12A, and HMVECd were grown in the presence
of hydrocortisone as customarily present in growth media or in its
absence. Cells were grown from 7 to 14 days as specified before
assessing FAP activity and FAP protein levels. (A) FAP activity was
measured as previously described. FAP activity in the absence of
hyc was set at 100%, with the level of FAP activity in the presence
of hyc expressed as a relative percent. (B) Immunostains of cell
lysates from fibroblast, normal breast, and EC cultures, using mAb
6D2 to FAP. APCE (1 ng) is used as a positive control; α-tubulin (50 kDa)
and actin (43 kDa) were used to standardize cell lysate protein amounts
applied to each electrophoretic lane. MCF-12A were grown in the
absence of hyc, (−)hyc, for 7 days, followed by repletion of the
normal media (+)hyc content, as supplied by Lonza, for 7 days,
labeled (−)hyc/(+)hyc, before assessing both FAP activity and FAP
protein concentration.
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appeared to increase in conjunction with advancing gelatinolytic ac-
tivity during in vitro tube formation. A few other studies have also
suggested that ECs within the developing microvasculature of malig-
nant tissues do indeed express FAP [7,40,52].
As shown by immunoblot analysis and activity assays (Figure 7),
stress caused by removal of hyc from growth media stimulated both
HMVECd and MCF-12A to overexpress FAP as identified by amino
acid sequence (Figure 2). Notably, replenishment of hyc returned
FAP expression to levels before hyc removal (Figure 7). Similarly,
WI-38 activated fibroblasts, which are ordinarily grown in the absence
of hyc, showed a detectable decrease in FAP expression when hyc was
added. Analogous effects with hyc have been noted before, e.g.,
decreased hyc in normal human epithelial cells was associated with
increases of urokinase and tissue plasminogen activator [53]. These
data suggest that cells are capable of altering expression of FAP if they
should become stressed as might occur in a rapidly expanding meta-
static tumor microenvironment.
MSCs give rise to progenitor adipocytes, bone cells, and myocytes
and are also considered precursive to fibroblasts [44,54]. Conceivably,
activated MSCs could arise as a consequence of epithelial-mesenchymal
cell transformation [55] and represent the progenitor cell of the “tumor
niche.” Some propose, however, that MSCs originate from the bone
marrow, move into a selected tissue, and undergo malignant transfor-
mation to produce cancer cells characteristic of that tissue [41,56].
Others consider that a precursive cancer stem cell might derive from
a dormant multipotent cell unique to a specific tissue. The amounts
of FAP we observed for MSCs by confocal microscopy and Western
blot analysis (Figure 8) were more than for WI-38 activated fibroblasts
(Figure 1). The multiple roles of mesenchymal cells suggest they may
exist in an activated state more frequently than do fibroblasts. This may
be particularly true with respect to mesenchymal cell involvement in
malignancies and account for the large amount of FAP we observed
in these cells.
Our results allow the following conclusions: 1) FAP is uniquely
expressed on the membranes of cells critical to tumor niche forma-
tion in primary tumors or metastases, namely, cancer-associated
fibroblasts, MSCs, selected cancer cells, and ECs as the latter partic-
ipate in angiogenesis; POP in general is overexpressed in cells of the
tumor niche. 2) In their membrane-bound form, each enzyme is pro-
teolytically active and easily accessible for efficient inhibition by a
new soluble, high-affinity, selective pseudo-peptide inhibitor that meets
structural requirements for the respective enzyme’s substrate-binding
region. 3) ECs readily express POP as they grow, and in addition,
membrane-inserted proteolytically active FAP is synthesized and ex-
pressed as tubulogenesis occurs [39,52]. 4) FAP and POP hold promise
as therapeutic targets for a large number of cancers and the two new
inhibitors, M83 and J94, may be useful for determining if inhibition
of one or both proteolytic activities will deter or abolish growth of com-
monly encountered epithelial-derived cancers and their metastatic foci.
Results reported here now point toward further studies of the inhibi-
tors’ potential therapeutic effects on selected epithelial-derived human
tumor xenograft models in immunocompromised mice.
References
[1] Garin-Chesa P, Old LJ, and Rettig WJ (1990). Cell surface glycoprotein of
reactive stromal fibroblasts as a potential antibody target in human epithelial
cancers. Proc Natl Acad Sci USA 87, 7235–7239.
[2] Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, and Rettig WJ
(1999). Fibroblast activation protein, a dual specificity serine protease expressed
in reactive human tumor stromal fibroblasts. J Biol Chem 274, 36505–36512.
[3] Rettig WJ, Garin-Chesa P, Beresford HR, Oettgen HF, Melamed MR, and Old LJ
(1988). Cell-surface glycoproteins of human sarcomas: differential expression in normal
and malignant tissues and cultured cells. Proc Natl Acad Sci USA 85, 3110–3114.
Figure 8. Identification and characterization of FAP and POP in human MSCs. (A) Confocal image of permeabilized MSCs was grown on
glass slides and labeled with mAb F19 to FAP followed by anti–mouse Alexa Fluor 568 (red) and DAPI (green). (B) FAP and POP activities
found on MSC surfaces grown in plastic wells were measured exactly the same as described in Figures 1 and 4. (C) Immunostaining for
FAP was performed as described in Figures 1 and 4. (D) Immunostaining for FAP in cell lysates and membrane and cytosolic fractions of
MSCs was performed as described in Figure 1. (E) Immunostaining for POP was performed as described in Figures 1 and 4. (F) Immuno-
staining for POP in cell lysates and membrane and cytosolic fractions of MSCs was performed as described in Figure 1.
356 FAP-α and POP Inhibition Christiansen et al. Neoplasia Vol. 15, No. 4, 2013
[4] Niedermeyer J, Garin-Chesa P, Kriz M, Hilberg F, Mueller E, Bamberger U,
Rettig WJ, and Schnapp A (2001). Expression of the fibroblast activation pro-
tein during mouse embryo development. Int J Dev Biol 45, 445–447.
[5] Acharya PS, Zukas A, Chandan V, Katzenstein AL, and Puré E (2006). Fibro-
blast activation protein: a serine protease expressed at the remodeling interface in
idiopathic pulmonary fibrosis. Hum Pathol 37, 352–360.
[6] Wang XM, Yao TW, Nadvi NA, Osborne B, McCaughan GW, and Gorrell
MD (2008). Fibroblast activation protein and chronic liver disease. Front Biosci
13, 3168–3180.
[7] Ge Y, Zhan F, Barlogie B, Epstein J, Shaughnessy J Jr, and Yaccoby S (2006).
Fibroblast activation protein (FAP) is upregulated in myelomatous bone and
supports myeloma cell survival. Br J Haematol 133, 83–92.
[8] Dohi O, Ohtani H, Hatori M, Sato E, Hosaka M, Nagura H, Itoi E, and
Kokubun S (2009). Histogenesis-specific expression of fibroblast activation pro-
tein and dipeptidylpeptidase-IV in human bone and soft tissue tumours. Histo-
pathology 55, 432–440.
[9] Bauer S, Jendro MC,Wadle A, Kleber S, Stenner F, Dinser R, Reich A, Faccin E,
Godde S, Dinges H, et al. (2006). Fibroblast activation protein is expressed by
rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther 8, R171.
[10] Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Ozer HL, Schwab M, Albino AP,
and Old LJ (1993). Regulation and heteromeric structure of the fibroblast activa-
tion protein in normal and transformed cells of mesenchymal and neuroectodermal
origin. Cancer Res 53, 3327–3335.
[11] Puré E (2009). The road to integrative cancer therapies: emergence of a tumor-
associated fibroblast protease as a potential therapeutic target in cancer. Expert
Opin Ther Targets 13, 967–973.
[12] Hayward SW (2010). Preclinical assessment of fibroblast activation protein as a
target for antitumor therapy. Future Oncol 6, 347–349.
[13] Kelly T, Huang Y, Simms AE, and Mazur A (2012). Fibroblast activation
protein-α: a key modulator of the microenvironment in multiple pathologies.
Int Rev Cell Mol Biol 297, 83–116.
[14] Liu R, Li H, Liu L, Yu J, and Ren X (2012). Fibroblast activation protein: a
potential therapeutic target in cancer. Cancer Biol Ther 13, 123–129.
[15] Lee KN, Jackson KW, Christiansen VJ, Lee CS, Chun JG, and McKee PA
(2006). Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation
protein. Blood 107, 1397–1404.
[16] Aggarwal S, Brennen WN, Kole TP, Schneider E, Topaloglu O, Yates M, Cotter
RJ, and Denmeade SR (2008). Fibroblast activation protein peptide substrates
identified from human collagen I derived gelatin cleavage sites. Biochemistry 47,
1076–1086.
[17] Niedermeyer J, Scanlan MJ, Garin-Chesa P, Daiber C, Fiebig HH, Old LJ,
Rettig WJ, and Schnapp A (1997). Mouse fibroblast activation protein: molec-
ular cloning, alternative splicing and expression in the reactive stroma of epi-
thelial cancers. Int J Cancer 71, 383–389.
[18] Christiansen VJ, Jackson KW, Lee KN, and McKee PA (2007). Effect of fibro-
blast activation protein and α2-antiplasmin cleaving enzyme on collagen types I,
III, and IV. Arch Biochem Biophys 457, 177–186.
[19] Huang Y, Wang S, and Kelly T (2004). Seprase promotes rapid tumor growth and
increased microvessel density in a mouse model of human breast cancer. Cancer Res
64, 2712–2716.
[20] Cheng JD andWeiner LM (2003). Tumors and their microenvironments: tilling
the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of
sibrotuzumab in patients with advanced or metastatic fibroblast activation
protein-positive cancer. Clin. Cancer Res., 9: 1639–1647, 2003. Clin Cancer Res
9, 1590–1595.
[21] Kalluri R and Zeisberg M (2006). Fibroblasts in cancer. Nat Rev Cancer 6,
392–401.
[22] Santos AM, Jung J, Aziz N, Kissil JL, and Puré E (2009). Targeting fibroblast
activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest
119, 3613–3625.
[23] Kelly T, Adams J, Bachovchin W, Barton R, Campbell S, Courts S, Kennedy C,
and Snow R (1993). Immunosuppressive boronic acid dipeptides: correlation
between conformation and activity. J Am Chem Soc 115, 12637–12638.
[24] Rosenblum JS and Kozarich JW (2003). Prolyl peptidases: a serine protease
subfamily with high potential for drug discovery. Curr Opin Chem Biol 7,
496–504.
[25] Narra K, Mullins SR, Lee HO, Strzemkowski-Brun B, Magalong K, Christiansen
VJ, McKee PA, Egleston B, Cohen SJ, Weiner LM, et al. (2007). Phase II trial of
single agent Val-boroPro (Talabostat) inhibiting fibroblast activation protein in
patients with metastatic colorectal cancer. Cancer Biol Ther 6, 1691–1699.
[26] Goossens F, De Meester I, Vanhoof G, and Scharpé S (1996). Distribution of
prolyl oligopeptidase in human peripheral tissues and body fluids. Eur J Clin
Chem Clin Biochem 34, 17–22.
[27] Liu JM, Kusinski M, Ilic V, Bignon J, Hajem N, Komorowski J, Kuzdak K,
Stepien H, and Wdzieczak-Bakala J (2008). Overexpression of the angiogenic
tetrapeptide AcSDKP in humanmalignant tumors. Anticancer Res 28, 2813–2817.
[28] Lee KN, Jackson KW, Christiansen VJ, Dolence EK, and McKee PA (2011).
Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-
antiplasmin. J Thromb Haemost 9, 987–996.
[29] Lee KN, Jackson KW, Christiansen VJ, Chung KH, and McKee PA (2004). A
novel plasma proteinase potentiates α2-antiplasmin inhibition of fibrin diges-
tion. Blood 103, 3783–3788.
[30] Lee KN, Jackson KW, Terzyan S, Christiansen VJ, and McKee PA (2009).
Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activa-
tion protein inhibitor design. Biochemistry 48, 5149–5158.
[31] Gorrao SS, Hemerly JP, Lima AR, Melo RL, Szeltner Z, Polgar L, Juliano MA,
and Juliano L (2007). Fluorescence resonance energy transfer (FRET) peptides
and cycloretro-inverso peptides derived from bradykinin as substrates and inhibi-
tors of prolyl oligopeptidase. Peptides 28, 2146–2154.
[32] Szeltner Z and Polgar L (2008). Structure, function and biological relevance of
prolyl oligopeptidase. Curr Protein Pept Sci 9, 96–107.
[33] Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH,
Old LJ, and Rettig WJ (1994). Molecular cloning of fibroblast activation pro-
tein α, a member of the serine protease family selectively expressed in stromal
fibroblasts of epithelial cancers. Proc Natl Acad Sci USA 91, 5657–5661.
[34] Larrinaga G, Perez I, Blanco L, Lopez JI, Andres L, Etxezarraga C, Santaolalla F,
Zabala A, Varona A, and Irazusta J (2010). Increased prolyl endopeptidase
activity in human neoplasia. Regul Pept 163, 102–106.
[35] Busek P, Stremenova J, and Sedo A (2008). Dipeptidyl peptidase-IV enzymatic
activity bearing molecules in human brain tumors—good or evil? Front Biosci
13, 2319–2326.
[36] Liu JM, Garcia-Alvarez MC, Bignon J, Kusinski M, Kuzdak K, Riches A, and
Wdzieczak-Bakala J (2010). Overexpression of the natural tetrapeptide acetyl-N -
ser-asp-lys-pro derived from thymosin β4 in neoplastic diseases. Ann N Y Acad
Sci 1194, 53–59.
[37] Myohanen TT, Tenorio-Laranga J, Jokinen B, Vazquez-Sanchez R, Moreno-
Baylach MJ, Garcia-Horsman JA, and Mannisto PT (2011). Prolyl oligopepti-
dase induces angiogenesis both in vitro and in vivo in a novel regulatory manner.
Br J Pharmacol 163, 1666–1678.
[38] Wang T and Shi W (2009). Expression of fibroblast activation proteins in corneal
stromal neovascularization. Curr Eye Res 34, 112–117.
[39] Aimes RT, Zijlstra A, Hooper JD, Ogbourne SM, Sit ML, Fuchs S, Gotley DC,
Quigley JP, and Antalis TM (2003). Endothelial cell serine proteases expressed
during vascular morphogenesis and angiogenesis. Thromb Haemost 89, 561–572.
[40] Okada K, Chen WT, Iwasa S, Jin X, Yamane T, Ooi A, and Mitsumata M
(2003). Seprase, a membrane-type serine protease, has different expression patterns
in intestinal- and diffuse-type gastric cancer. Oncology 65, 363–370.
[41] Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson
AL, Polyak K, Tubo R, and Weinberg RA (2007). Mesenchymal stem cells
within tumour stroma promote breast cancer metastasis. Nature 449, 557–563.
[42] Coghlin C and Murray GI (2010). Current and emerging concepts in tumour
metastasis. J Pathol 222, 1–15.
[43] Bae S, Park CW, Son HK, Ju HK, Paik D, Jeon CJ, Koh GY, Kim J, and Kim H
(2008). Fibroblast activation protein α identifies mesenchymal stromal cells
from human bone marrow. Br J Haematol 142, 827–830.
[44] Emura M, Ochiai A, Horino M, Arndt W, Kamino K, and Hirohashi S (2000).
Development of myofibroblasts from human bone marrow mesenchymal stem
cells cocultured with human colon carcinoma cells and TGF beta 1. In Vitro
Cell Dev Biol Anim 36, 77–80.
[45] Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO,
Gopinathan A, Tuveson DA, and Fearon DT (2010). Suppression of antitumor
immunity by stromal cells expressing fibroblast activation protein–α. Science
330, 827–830.
[46] Huang Y, Simms AE, Mazur A, Wang S, Leon NR, Jones B, Aziz N, and Kelly T
(2011). Fibroblast activation protein-α promotes tumor growth and invasion of
breast cancer cells through non-enzymatic functions. Clin Exp Metastasis 6,
567–579.
[47] Brennen WN, Rosen DM, Wang H, Isaacs JT, and Denmeade SR (2012).
Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibro-
blast activation protein-activated prodrug. J Natl Cancer Inst 104, 1320–1334.
Neoplasia Vol. 15, No. 4, 2013 FAP-α and POP Inhibition Christiansen et al. 357
[48] Christiansen VJ, Jackson KW, Lee KN, and McKee PA (2007). The effect of a
single nucleotide polymorphism on human α2-antiplasmin activity. Blood 109,
5286–5292.
[49] Duke-Cohan JS, Morimoto C, Rocker JA, and Schlossman SF (1995). A novel
form of dipeptidylpeptidase IV found in human serum. Isolation, characteriza-
tion, and comparison with T lymphocyte membrane dipeptidylpeptidase IV
(CD26). J Biol Chem 270, 14107–14114.
[50] Garcia-Horsman JA, Mannisto PT, and Venalainen JI (2007). On the role of
prolyl oligopeptidase in health and disease. Neuropeptides 41, 1–24.
[51] Cavallo-Medved D, Rudy D, Blum G, Bogyo M, Caglic D, and Sloane BF
(2009). Live-cell imaging demonstrates extracellular matrix degradation in
association with active cathepsin B in caveolae of endothelial cells during tube
formation. Exp Cell Res 315, 1234–1246.
[52] Bhati R, Patterson C, Livasy CA, Fan C, Ketelsen D, Hu Z, Reynolds E,
Tanner C, Moore DT, Gabrielli F, et al. (2008). Molecular characterization
of human breast tumor vascular cells. Am J Pathol 172, 1381–1390.
[53] Myohanen H, Virtanen I, and Vaheri A (2001). Elimination of hydrocortisone from
the medium enables tissue plasminogen activator gene expression by normal and
immortalized nonmalignant human epithelial cells. Biol Chem 382, 1563–1573.
[54] Mishra PJ, Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, Ganesan
S, Glod JW, and Banerjee D (2008). Carcinoma-associated fibroblast–like
differentiation of human mesenchymal stem cells. Cancer Res 68, 4331–4339.
[55] Thiery JP, Acloque H, Huang RY, and NietoMA (2009). Epithelial-mesenchymal
transitions in development and disease. Cell 139, 871–890.
[56] Baguley BC (2006). Tumor stem cell niches: a new functional framework for
the action of anticancer drugs. Recent Pat Anticancer Drug Discov 1, 121–127.
358 FAP-α and POP Inhibition Christiansen et al. Neoplasia Vol. 15, No. 4, 2013
